Integra LifeSciences Holdings Corporation — Form 8-K Summary
Event and period: Filed October 2, 2026, reporting preliminary, unaudited results for the third quarter ended September 30, 2026. The filing does not provide a complete set of quarterly financial results.
Preliminary financial metrics
- Reported revenue: Expected to be $410 million to $412 million, including an estimated $7 million impact from flooding-related supply disruptions at the Cincinnati, Ohio manufacturing facility.
- Adjusted earnings per diluted share: Expected to be $0.55 to $0.59. This is a non-GAAP measure; the company did not provide a GAAP reconciliation because certain expense items could not be reasonably predicted.
- Operating cash flow: Expected to exceed $85 million.
- Other metrics: The filing does not provide clear values for GAAP profit, margins, debt, or liquidity.
Changes, outlook, and risks
- The filing gives no prior-period comparison, so changes versus the third quarter of 2025 cannot be assessed from this information.
- The company cites flooding-related supply disruptions at its Cincinnati facility. It identifies recovery progress and timing, recovery costs, potential asset impairments, and insurance coverage and recoveries as uncertain.
- Fiscal 2026 guidance is referenced as subject to risk, but this filing provides no guidance figures.
- The results are preliminary, unaudited, based on currently available information, and subject to completion of closing procedures; they have not been reviewed by the independent auditor. Actual results may differ materially.
Investor verification points
- Confirm final third-quarter revenue, adjusted EPS, and operating cash flow when reported.
- Review the eventual GAAP results and reconciliation to adjusted EPS.
- Check updated estimates of the Cincinnati flooding’s financial impact, recovery costs, and production recovery timeline.
- Verify insurance coverage and recoveries, any impairment charges, and the company’s current fiscal 2026 guidance.